Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRAALL-2003
- Development stage
- Unknown
- Lead developer
- Group for Research on Adult Acute Lymphoblastic Leukemia
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous, Intramuscular, Subcutaneous, Intrathecal
01
Overview
GRAALL-2003 is not a single drug but a multi-agent chemotherapy regimen developed as a pediatric-inspired treatment protocol for adults (ages 15–60) with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-negative ALL). The regimen was designed by the Group for Research on Adult Acute Lymphoblastic Leukemia and incorporates intensified doses of nonmyelotoxic drugs commonly used in pediatric protocols, such as prednisone, vincristine, and L-asparaginase. The treatment includes several phases—induction, consolidation blocks with high dose-intensity, delayed intensification, and two years of maintenance therapy. Some adult-specific options like allogeneic stem cell transplantation were retained for high-risk patients. The regimen demonstrated improved complete remission rates and survival outcomes compared to previous adult protocols[1][2][4].
- Other names
- GRAALL-2003 protocolGRAALL2003 protocolGRAALL 2003 protocolGroup for Research on Adult Acute Lymphoblastic Leukemia 2003 protocol
02
Targets
TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)ASNase (L-asparaginase)DNA interstrand cross-linkTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on GRAALL-2003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRAALL-2003.